202 related articles for article (PubMed ID: 28220608)
21. Successful treatment of Kasabach-Merritt syndrome arising from kaposiform hemangioendothelioma by systemic corticosteroid therapy and surgery.
Jiang RS; Hu R
Int J Clin Oncol; 2012 Oct; 17(5):512-6. PubMed ID: 21947597
[TBL] [Abstract][Full Text] [Related]
22. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
23. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Wang Z; Li K; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2014 Aug; 61(8):1518-9. PubMed ID: 24482015
[No Abstract] [Full Text] [Related]
24. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: successful treatment with vincristine and ticlopidine.
Barabash-Neila R; García-Rodríguez E; Bernabeu-Wittel J; Bueno-Rodríguez I; Ramírez-Villar G; López-Gutierrez JC
Indian J Pediatr; 2012 Oct; 79(10):1386-7. PubMed ID: 22161581
[No Abstract] [Full Text] [Related]
25. Successful Use of Sirolimus in Children With Large Mesenteric Lymphatic Lesions.
Gastineau S; Paolella G; Talbotec C; Verkarre V; Sauvat F; Goulet O; Fraitag S; Lacaille F
J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):e24-e25. PubMed ID: 28777125
[No Abstract] [Full Text] [Related]
26. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
27. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
28. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
29. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.
Tasani M; Ancliff P; Glover M
Br J Dermatol; 2017 Dec; 177(6):e344-e346. PubMed ID: 28485019
[No Abstract] [Full Text] [Related]
30. A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas.
Ying H; Qiao C; Yang X; Lin X
Pediatrics; 2018 Apr; 141(Suppl 5):S425-S429. PubMed ID: 29610165
[TBL] [Abstract][Full Text] [Related]
31. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
32. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
33. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants.
Harbers VEM; van der Salm N; Pegge SAH; van der Vleuten CJM; Verhoeven BH; Vrancken SLAG; Schultze Kool LJ; Fuijkschot J; Te Loo DMMWM
Br J Clin Pharmacol; 2022 Jun; 88(6):2769-2781. PubMed ID: 34957601
[TBL] [Abstract][Full Text] [Related]
34. Kasabach-Merritt syndrome, kaposiform haemangioendothelioma and platelet blockade.
O'Rafferty C; O'Regan GM; Irvine AD; Smith OP
Br J Haematol; 2015 Oct; 171(1):11. PubMed ID: 26114338
[No Abstract] [Full Text] [Related]
35. Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report.
Cheng J; Zou Y; Fu R; Jin P; Huang M; Wu Z; Bai H; Huang X; Yuan H
Medicine (Baltimore); 2024 Apr; 103(14):e37706. PubMed ID: 38579031
[TBL] [Abstract][Full Text] [Related]
36. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
37. Kaposiform hemangioendothelioma: therapeutic efficacy for an enigmatic diagnosis.
Blei F
Pediatr Blood Cancer; 2015 Apr; 62(4):551-2. PubMed ID: 25559734
[No Abstract] [Full Text] [Related]
38. First Intracardiac Kaposiform Hemangioendothelioma in an Infant Resolved With Sirolimus: A Case Report.
Zaidi SJ; Shaik S; Agrawal C; Cossor W
J Pediatr Hematol Oncol; 2018 Oct; 40(7):536-540. PubMed ID: 30067556
[TBL] [Abstract][Full Text] [Related]
39. Management of Refractory Pediatric Kaposiform Hemangioendothelioma With Sirolimus and Aspirin.
MacFarland SP; Sullivan LM; States LJ; Bailey LC; Balamuth NJ; Womer RB; Olson TS
J Pediatr Hematol Oncol; 2018 May; 40(4):e239-e242. PubMed ID: 29240034
[TBL] [Abstract][Full Text] [Related]
40. Kaposiform haemangioendothelioma in a nine-year-old boy with Kasabach-Merritt phenomenon.
Zhang G; Gao Y; Liu X
Br J Haematol; 2017 Oct; 179(1):9. PubMed ID: 28714059
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
